BiotechTube
Inflammasome Therapeutics

Inflammasome Therapeutics

Cambridge, United States· Est.
inflam.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

Inflammasome Therapeutics is a private, clinical-stage biotech pioneering a new approach to treating degenerative diseases by targeting chronic inflammasome activation. Its platform is built upon the discovery that certain FDA-approved nucleoside reverse transcriptase inhibitors (NRTIs) inhibit inflammasomes, supported by epidemiological data showing reduced disease incidence in patients taking these drugs. The company has developed safer derivatives called Kamuvudines (K8, K9) and is advancing them in clinical trials for ocular indications including Geographic Atrophy, Diabetic Macular Edema, and Thyroid Eye Disease.

OphthalmologyNeurodegenerative DiseasesMetabolic Diseases

Technology Platform

Kamuvudine platform: novel small molecule derivatives of NRTIs designed to inhibit aberrant inflammasome activation and the associated inflammatory cytokine cascade (IL-1β, IL-18, etc.) with a improved safety profile, avoiding the mitochondrial toxicity of the parent compounds.

Funding History

3
Total raised:$150M
Series B$100M
Series A$40M
Seed$10M

Opportunities

The recent approval of therapies for Geographic Atrophy validates the market and creates urgency for improved treatments.
An effective oral therapy for Diabetic Macular Edema or Thyroid Eye Disease would offer a major convenience advantage over current injection-based standards of care, enabling significant market penetration.
The platform's potential application to large neurodegenerative markets like Alzheimer's disease represents a long-term, high-value opportunity.

Risk Factors

The core risk is clinical failure, as the novel inflammasome inhibition mechanism must prove safe and effective in humans despite promising preclinical data.
The company faces intense competition in ophthalmology from larger, well-resourced players.
As a private, pre-revenue biotech, it carries significant financial risk and dependence on future fundraising to advance its pipeline.

Competitive Landscape

In Geographic Atrophy, Inflammasome Therapeutics competes with newly approved complement inhibitors (Apellis's Syfovre, Iveric Bio's Izervay) and other late-stage players. In Diabetic Macular Edema, the market is dominated by anti-VEGF injections (Regeneron, Roche). The company's differentiation lies in its novel mechanism (inflammasome inhibition) and its development of convenient delivery formats (oral, sustained-release implant) aimed at improving patient adherence and outcomes.

More companies in Small Molecule Drugs →More companies in United States →